NCT01327521: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma |
|
|
| Withdrawn | 3 | 0 | US | CyberKnife, CK, TACE, Transcatheter arterial chemoembolization, CT Contrast, contrast dye, doxorubicin, Adriamycin, hydroxydaunorubicin, Epirubicin, Ellence, Pharmorubicin, Epirubicin Ebewe, 5-fluorouracil, 5-FU, f5U, Adrucil, Carac, Efudix, Efudex, Fluoroplex, Mitomycin C, Mutamycin, MTC, Gemcitabine, Gemzar, Cisplatin, cisplatinum, cis-diamminedichloroplatinum(II), CDDP, Platinol, Platinol-AQ, SMANCS, styrene maleic acid neocarzinostatin, poppyseed oil | Albert Koong, Accuray Incorporated | Carcinoma, Hepatocellular | 02/14 | | | |
RILOMET-1, NCT01697072 / 2011-004923-11: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Terminated | 3 | 609 | US, Canada, Europe, RoW | Rilotumumab, AMG102, Placebo, sterile protein-free solution, Epirubicin, Ellence, Pharmorubicin PFS, Pharmorubicin RDF, Cisplatin, Platinol, Platinol-AQ, Capecitabine, Xeloda | Amgen | Gastric Cancer | 11/14 | 08/15 | | |
| Active, not recruiting | 3 | 788 | Europe | cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine | Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG | Gastric Cancer | 12/18 | 12/25 | | |
